Study · Randomized controlled trial · 2017

5 results

Comparison of Efficacy and Safety of Liraglutide 3.0 mg in Individuals with BMI above and below 35 kg/m²: A Post-hoc Analysis.

le Roux C, Aroda V, Hemmingsson J, Cancino AP, Christensen R, Pi-Sunyer X

Obesity facts17 Nov 2017Cited by 28 (Europe PMC)

PMID29145215PMCIDPMC5836203DOI10.1159/000478099PepBankPUB-29145215

Read at source PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC-ND. Results still quote short attributed sentences.

Results from this study5

5 results from studies that gave the peptide. 5 results from people.

01HumanRandomized controlled trialEfficacy outcome
In adults with overweight or obesity, with or without type 2 diabetes, liraglutide 3.0 mg produced significantly greater weight loss than placebo in all patient groups.
In plain wordsIn people with overweight or obesity, with or without type 2 diabetes, liraglutide 3.0 mg led to more weight loss than placebo.
Peptide
Liraglutide
Outcome
DecreaseWeight loss (0-56 weeks) versus placebo
Study
n: not reported in source
Comparator
Placebo
Outcome group
Body weight · Metabolic and weight
Studied dose
3.0 mg · 56 weeksAs given in this study (human).
Source sentences
Summary
Significantly greater weight loss (0-56 weeks) was observed with liraglutide 3.0 mg versus placebo in all patient groups while on treatment.
2 context sentences(design, population, supporting numbers)
Summary · context
To investigate whether the efficacy and safety of liraglutide 3.0 mg differed between two subgroups, BMI 27 to <35 and BMI ≥ 35 kg/m², in individuals without and with type 2 diabetes (T2D).
Summary · context
A post-hoc analysis of two 56-week, randomized, double-blind, placebo-controlled trials (SCALE Obesity and Prediabetes; SCALE Diabetes).
Report a problemFND-2914521501
02HumanRandomized controlled trialEfficacy outcome
In adults with overweight or obesity, the weight-lowering effect of liraglutide 3.0 mg did not differ between the BMI 27 to <35 and BMI 35 or higher subgroups.
In plain wordsIn people with overweight or obesity, liraglutide 3.0 mg lowered weight about equally in people with a lower and a higher BMI.
Peptide
Liraglutide
Outcome
No significant changeWeight loss by BMI subgroup (interaction)
Study
n: not reported in source
Comparator
BMI subgroup
Outcome group
Body weight · Metabolic and weight
Studied dose
3.0 mg · 56 weeksAs given in this study (human).
Source sentences
Summary
There was no evidence that the weight-lowering effect of liraglutide 3.0 mg differed between BMI subgroups (interaction p > 0.05).
2 context sentences(design, population, supporting numbers)
Summary · context
To investigate whether the efficacy and safety of liraglutide 3.0 mg differed between two subgroups, BMI 27 to <35 and BMI ≥ 35 kg/m², in individuals without and with type 2 diabetes (T2D).
Summary · context
A post-hoc analysis of two 56-week, randomized, double-blind, placebo-controlled trials (SCALE Obesity and Prediabetes; SCALE Diabetes).
Report a problemFND-2914521502
03HumanRandomized controlled trialEfficacy outcome
In adults with overweight or obesity, liraglutide 3.0 mg gave significantly greater improvements than placebo for most secondary endpoints.
In plain wordsIn people with overweight or obesity, liraglutide 3.0 mg improved most secondary measures more than placebo.
Peptide
Liraglutide
Outcome
MixedSecondary endpoints versus placebo
Study
n: not reported in source
Comparator
Placebo
Outcome group
Cardiometabolic risk factors · Metabolic and weight
Studied dose
3.0 mg · 56 weeksAs given in this study (human).
Source sentences
Summary
Similarly, for most secondary endpoints significantly greater improvements were observed with liraglutide 3.0 mg versus placebo
2 context sentences(design, population, supporting numbers)
Summary · context
To investigate whether the efficacy and safety of liraglutide 3.0 mg differed between two subgroups, BMI 27 to <35 and BMI ≥ 35 kg/m², in individuals without and with type 2 diabetes (T2D).
Summary · context
A post-hoc analysis of two 56-week, randomized, double-blind, placebo-controlled trials (SCALE Obesity and Prediabetes; SCALE Diabetes).
Report a problemFND-2914521503
04HumanRandomized controlled trialEfficacy outcome
In adults with overweight or obesity, treatment effects of liraglutide 3.0 mg on secondary endpoints did not differ between BMI subgroups.
In plain wordsIn people with overweight or obesity, liraglutide 3.0 mg worked similarly on secondary measures in lower and higher BMI groups.
Peptide
Liraglutide
Outcome
No significant changeSecondary endpoints by BMI subgroup
Study
n: not reported in source
Comparator
BMI subgroup
Outcome group
Cardiometabolic risk factors · Metabolic and weight
Studied dose
3.0 mg · 56 weeksAs given in this study (human).
Source sentences
Summary
Similarly, for most secondary endpoints significantly greater improvements were observed with liraglutide 3.0 mg versus placebo, with no indication treatment effects differing between subgroups.
2 context sentences(design, population, supporting numbers)
Summary · context
To investigate whether the efficacy and safety of liraglutide 3.0 mg differed between two subgroups, BMI 27 to <35 and BMI ≥ 35 kg/m², in individuals without and with type 2 diabetes (T2D).
Summary · context
A post-hoc analysis of two 56-week, randomized, double-blind, placebo-controlled trials (SCALE Obesity and Prediabetes; SCALE Diabetes).
Report a problemFND-2914521504
05HumanRandomized controlled trialSafety outcome
In adults with overweight or obesity, the safety profile of liraglutide 3.0 mg was broadly similar across BMI subgroups.
In plain wordsIn people with overweight or obesity, liraglutide 3.0 mg had a broadly similar safety profile in lower and higher BMI groups.
Peptide
Liraglutide
Outcome
No significant changeSafety profile by BMI subgroup
Study
n: not reported in source
Comparator
BMI subgroup
Outcome group
Adverse events · Whole body
Studied dose
3.0 mg · 56 weeksAs given in this study (human).
Source sentences
Summary
The safety profile of liraglutide 3.0 mg was broadly similar across BMI subgroups.
2 context sentences(design, population, supporting numbers)
Summary · context
To investigate whether the efficacy and safety of liraglutide 3.0 mg differed between two subgroups, BMI 27 to <35 and BMI ≥ 35 kg/m², in individuals without and with type 2 diabetes (T2D).
Summary · context
A post-hoc analysis of two 56-week, randomized, double-blind, placebo-controlled trials (SCALE Obesity and Prediabetes; SCALE Diabetes).
Report a problemFND-2914521505

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials2

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

2 trials · 2 completed · 2 with posted results · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 3Results postedNCT01272219

Effect of Liraglutide on Body Weight in Non-diabetic Obese Subjects or Overweight Subjects With Co-morbidities: SCALE™ - Obesity and Pre-diabetes

Novo Nordisk A/Sn = 3,7311 Jun 2011 to 2 Mar 2015

Metabolism and Nutrition Disorder · Obesity

Trial page ClinicalTrials.govUpdated 19 Jan 2018

CompletedPhase 3Results postedNCT01272232

Effect of Liraglutide on Body Weight in Overweight or Obese Subjects With Type 2 Diabetes: SCALE™ - Diabetes

Novo Nordisk A/Sn = 8461 Jun 2011 to 25 Jan 2013

Metabolism and Nutrition Disorder · Obesity

Trial page ClinicalTrials.govUpdated 29 Dec 2017

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
12 Oct 2026, 12:10 UTC
Study results updated
Version 1
9 Oct 2026, 03:05 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.